Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.70 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.70 |
| ▸ | FLT1 | P17948 | 1/20 | 0.63 |
| ▸ | FLT4 | P35916 | 1/20 | 0.63 |
| ▸ | KDR | P35968 | 1/20 | 0.63 |
| ▸ | DDX3X | O00571 | 1/20 | 0.61 |
| ▸ | FBP1 | P09467 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | MMP1 | P03956 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.56 |
| ▸ | MMP8 | P22894 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | EEF2K | O00418 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | KDM1A | O60341 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10529379 | 0.92 | CRHBP (0.82) | CRHBPCRHR2FLT1FLT4KDR | |
| SCHEMBL11872858 | 0.86 | DDX3X (0.71) | CRHBPCRHR2FLT1FLT4KDR | |
| SCHEMBL21328474 | 0.85 | KDR (0.61) | CRHBPCRHR2FLT1FLT4KDR | |
| SCHEMBL28730744 | 0.84 | CRHBP (0.62) | CRHBPCRHR2FLT1FLT4KDR | |
| SCHEMBL8309888 | 0.82 | CRHBP (1.00) | CRHBPCRHR2DDX3XCA2ALDH1A1 | |
| SCHEMBL5228114 | 0.82 | ALDH1A1 (0.71) | FLT1FLT4KDRDDX3XFBP1 | |
| SCHEMBL9515445 | 0.82 | CRHBP (0.74) | CRHBPCRHR2DDX3XALDH1A1KMT2A | |
| SCHEMBL8248683 | 0.81 | ALDH1A1 (0.65) | FLT1FLT4KDRDDX3XFBP1 | |
| SCHEMBL10531035 | 0.80 | CRHBP (0.75) | CRHBPCRHR2DDX3XALDH1A1KMT2A | |
| SCHEMBL7612721 | 0.79 | CRHBP (0.70) | CRHBPCRHR2DDX3XCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1519932-B1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LTD (GB) | 2007-10-03 | — | — | EP | claimed |
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CYCLACEL LIMITED (GB) | 2005-09-29 | — | — | US | claimed |
| EP-1519932-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | Cyclacel Limited (GB) | 2005-04-06 | — | — | EP | claimed |
| WO-2004005278-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LIMITED (GB) | 2004-01-15 | — | — | WO | claimed |
| EP-1519932-B1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LTD (GB) | 2007-10-03 | — | — | EP | disclosed |
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CYCLACEL LIMITED (GB) | 2005-09-29 | — | — | US | disclosed |
| EP-1519932-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | Cyclacel Limited (GB) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004005278-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LIMITED (GB) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CCNL2, TP53, MDM2 | CRHBP 2050/4885CRHR2 3057/4885FLT1 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.